Symbols

URGN

UroGen Pharma·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About URGN

Urogen Pharma Ltd.

A biotech company that develops novel therapies for urothelial cancer treatment only in a water-based formulation

Industry

Pharmaceutical

Established Date

Listing Date

05/04/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

235

Fiscal Year Ends

12-31

Website

www.urogen.com

Security Type

Common stock

Office address

400 Alexander Park, Princeton, NJ, 08540

Business

Introduction

Urogen Pharma Ltd. was established under the laws of the State of Israel in April 2004 as TheraCoat Ltd. In September 2015, the company changed its name to Urogen Pharma Ltd.. The company is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care in urological pathology.

Earnings Call

Q1/2025

Estimate EPS-0.8

Actual EPS-0.92

Estimate Revenue22.70M

Actual Revenue20.25M

UroGen Pharma's Q1 2025: Navigating Key Contradictions in UGN-102's Approval and Market Strategy

May 20,2025 09:35·
Earnings Decrypt

Q2/2025

Estimate EPS-0.83

Actual EPS-1.05

Estimate Revenue23.13M

Actual Revenue24.20M

UroGen Pharma's Q2 2025: Navigating Contradictions in Market Penetration, Reimbursement, and FDA Expectations

Aug 08,2025 10:11·
Earnings Decrypt

Company Financials

EPS

URGN has released its 2025 Q3 earnings. EPS was reported at -0.69, versus the expected -0.68, missing expectations. The chart below visualizes how URGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

URGN has released its 2025 Q3 earnings report, with revenue of 27.48M, reflecting a YoY change of 9.04%, and net profit of -33.35M, showing a YoY change of -40.87%. The Sankey diagram below clearly presents URGN's revenue sources and cost distribution.